A carregar...
Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib
Background/Aim: The outcome of patients with advanced hepatocellular carcinoma (HCC) remains poor and therapeutic options, including sorafenib, the first anti-cancer drug proved to prolong survival in patients with advanced HCC, are limited. However, no clinically useful predictive biomarker for sor...
Na minha lista:
| Publicado no: | Cancer Genomics Proteomics |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Institute of Anticancer Research
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6885357/ https://ncbi.nlm.nih.gov/pubmed/31659110 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/cgp.20159 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|